Here’s why anti-vascular endothelial growth factor (VEGF) therapy may be a viable alternative to panretinal photocoagulation (PRP) in eyes with proliferative diabetic retinopathy (PDR).
After spending years encouraging and helping train colleagues to treat floaters, Christopher F. Wood, MD, is confident today’s technologies will allow ophthalmologists to popularize the procedure and expand access to many more patients.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
